Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines

被引：1

作者：

Escudier, Bernard ^{[1
]}

Joly, Florence ^{[2
]}

Soria, Jean-Charles ^{[3
]}

机构：

[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France

[2] Ctr Francois Baclesse, F-14076 Caen 05, France

[3] Inst Gustave Roussy, SITEP, F-94805 Villejuif, France

来源：

BULLETIN DU CANCER | 2011年 / 98卷

关键词：

renal cell carcinoma; immunotherapy; nephrectomy; anti-angiogenesis; mammalian target of rapamycin; guidelines; toxicities; CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; SUNITINIB;

D O I：

10.1684/bdc.2011.1444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted. Delta

引用

页码：S3 / S6

页数：4

共 50 条

[41] Pulmonary toxicities from targeted therapies: a review
Barber, Nicholas A.
Ganti, Apar Kishor
TARGETED ONCOLOGY, 2011, 6 (04) : 235 - 243
[42] Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients
Thornton, E.
Howard, S. A.
Jagannathan, J.
Krajewski, K. M.
Shinagare, A. B.
O'Regan, K.
Cleary, J. M.
Ramaiya, N. H.
BRITISH JOURNAL OF RADIOLOGY, 2012, 85 (1018): : 1420 - 1426
[43] Management of metastatic renal cell carcinoma in the era of targeted therapies
Webber, K.
Cooper, A.
Kleiven, H.
Yip, D.
Goldstein, D.
INTERNAL MEDICINE JOURNAL, 2011, 41 (08) : 594 - 605
[44] Targeted therapies in the management of renal cell carcinoma: role of bevacizuma
Escudier, Bernard
Cosaert, Jan
Jethwa, Sangeeta
BIOLOGICS-TARGETS & THERAPY, 2008, 2 (03): : 517 - 530
[45] Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
Cazzaniga, Marina Elena
Danesi, Romano
Girmenia, Corrado
Invernizzi, Pietro
Elvevi, Alessandra
Uguccioni, Massimo
Gila, Monica Perez
Amaducci, Laura
Atzori, Francesco
Blasi, Livio
Butti, Chiara
Collova, Elena
De Conciliis, Enrico
Fabi, Alessandra
Febbraro, Antonio
Garrone, Ornella
Gianni, Lorenzo
Giotta, Francesco
La Verde, Nicla
Michelotti, Andrea
Palumbo, Raffaella
Paris, Ida
Pistelli, Mirco
Pizzuti, Laura
Rubino, Daniela
Valerio, Maria Rosaria
Zustovich, Fable
BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) : 483 - 494
[46] Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
Marina Elena Cazzaniga
Romano Danesi
Corrado Girmenia
Pietro Invernizzi
Alessandra Elvevi
Massimo Uguccioni
Breast Cancer Research and Treatment, 2019, 176 : 483 - 494
[47] Japanese clinical guidelines for molecular targeted therapies in the treatment of thyroid cancer
Tahara, Makoto
ANNALS OF ONCOLOGY, 2017, 28 : 16 - 16
[48] Molecular targets and targeted therapies in bladder cancer management
Ramy F. Youssef
Anirban P. Mitra
Georg Bartsch
Peter A. Jones
Donald G. Skinner
Richard J. Cote
World Journal of Urology, 2009, 27
[49] MAPK Pathway - Targeted Therapies Care and management of unique toxicities in patients with advanced melanoma
Rubin, Krista M.
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (06) : 699 - 709
[50] Management of advanced bladder cancer in the era of targeted therapies
Soave, A.
Engel, O.
Von Amsberg, G.
Becker, A.
Dahlem, R.
Shariat, S. F.
Fisch, M.
Rink, M.
MINERVA UROLOGICA E NEFROLOGICA, 2015, 67 (02) : 103 - 115

← 1 2 3 4 5 →